Identifying a low‐flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial

The relationship between resting stroke volume (SV) and prognostic markers in heart failure with preserved ejection fraction (HFpEF) is not well established. We evaluated the association of SV index (SVI) at rest with exercise capacity and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) in stable patients with HFpEF.

[1]  J. Moon,et al.  Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. , 2019, JACC. Cardiovascular imaging.

[2]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[3]  P. Milani,et al.  Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis , 2018, Circulation. Cardiovascular imaging.

[4]  A. Bayés‐Genís,et al.  Peak Exercise Oxygen Uptake Predicts Recurrent Admissions in Heart Failure With Preserved Ejection Fraction. , 2017, Revista espanola de cardiologia.

[5]  E. Núñez,et al.  El consumo máximo de oxígeno predice los ingresos recurrentes por insuficiencia cardiaca con fracción de eyección conservada , 2017 .

[6]  Akshay S. Desai,et al.  Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. , 2017, JACC. Heart failure.

[7]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[8]  H. Rousseau,et al.  Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy , 2016, The International Journal of Cardiovascular Imaging.

[9]  E. González-López,et al.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.

[10]  Sanjiv J. Shah,et al.  Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone , 2015, Circulation.

[11]  T. Edvardsen,et al.  Left ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction , 2014, European heart journal cardiovascular Imaging.

[12]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[13]  W. Edwards,et al.  Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. , 2014, JACC. Heart failure.

[14]  Sanjiv J. Shah,et al.  Developing therapies for heart failure with preserved ejection fraction: current state and future directions. , 2014, JACC. Heart failure.

[15]  S. Solomon,et al.  Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis , 2014, Circulation.

[16]  E. Braunwald,et al.  Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study , 2014, Circulation. Heart failure.

[17]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[18]  W. Kraus,et al.  Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial. , 2013, European heart journal.

[19]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[20]  Jennifer G. Robinson,et al.  ACCF/AHA TASK FORCE MEMBERS , 2013 .

[21]  W. Kraus,et al.  Abstract 9925: Association between Resting Heart Rate, Chronotropic Index and Long-term Outcomes in Patients with Heart Failure Receiving Beta-blocker Therapy. Data from the HF-ACTION Trial , 2012 .

[22]  Luc Vanhees,et al.  Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations , 2012, Circulation.

[23]  E. Braunwald,et al.  PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. , 2012, Circulation. Heart failure.

[24]  D. Kitzman,et al.  Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. , 2012, Journal of the American College of Cardiology.

[25]  S. Fröhling,et al.  Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. , 2011, Journal of the American College of Cardiology.

[26]  R. McKelvie,et al.  Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial , 2011, Circulation. Heart failure.

[27]  R. Devereux,et al.  In-treatment stroke volume predicts cardiovascular risk in hypertension , 2011, Journal of hypertension.

[28]  Amir Lerman,et al.  Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. , 2010, Journal of the American College of Cardiology.

[29]  Z. Massy,et al.  Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. , 2008, European heart journal.

[30]  P. Pibarot,et al.  Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis Despite Preserved Ejection Fraction Is Associated With Higher Afterload and Reduced Survival , 2007, Circulation.

[31]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[32]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[33]  R. Arena,et al.  Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. , 2005, Journal of the American College of Cardiology.

[34]  M. Metra,et al.  β‐Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long‐term effects of atenolol vs. nebivolol , 2003, European journal of heart failure.

[35]  W. Hundley,et al.  Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. , 2002, JAMA.

[36]  M. Metra,et al.  Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. , 1999, Journal of the American College of Cardiology.